Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -56.27% is 166% below its 5-year average of -21.15%, near the low end of its 5-year range (-56.27%–19.82%).
48.16% below its 12-month average of -37.98%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -14.76%.
RETURN ON ASSETS (ROA)
-56.27%
RETURN ON ASSETS (ROA) AVG TTM
-37.98%
RETURN ON ASSETS (ROA) AVG 3Y
-21.94%
RETURN ON ASSETS (ROA) AVG 5Y
-21.15%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-48.16%
CURRENT VS 3Y AVG
-156.44%
CURRENT VS 5Y AVG
-166.05%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-74.40%
vs the sector median at left
Cullinan Therapeutics, Inc.
Market Cap
$998.69M
Return on Assets (ROA)
-56.27%
TTM Avg
-37.98%
3Y Avg
-21.94%
5Y Avg
-21.15%
Market Cap
$996.65M
Return on Assets (ROA)
-22.90%
TTM Avg
-17.96%
3Y Avg
-22.57%
5Y Avg
-25.02%
Market Cap
$992.14M
Return on Assets (ROA)
130.50%
TTM Avg
-115.89%
3Y Avg
-79.68%
5Y Avg
-67.37%
Market Cap
$1.01B
Return on Assets (ROA)
-43.17%
TTM Avg
-16.38%
3Y Avg
-11.13%
5Y Avg
-30.16%
Market Cap
$982.46M
Return on Assets (ROA)
-23.69%
TTM Avg
-98.11%
3Y Avg
-69.18%
5Y Avg
-69.18%
Market Cap
$981.66M
Return on Assets (ROA)
19.92%
TTM Avg
-50.75%
3Y Avg
-41.99%
5Y Avg
-34.79%
Market Cap
$1.02B
Return on Assets (ROA)
-3.46%
TTM Avg
-0.37%
3Y Avg
-7.11%
5Y Avg
-6.26%
Market Cap
$978.09M
Return on Assets (ROA)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$973.93M
Return on Assets (ROA)
1.18%
TTM Avg
-2.92%
3Y Avg
-0.56%
5Y Avg
1.87%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | $998.69M | -56.27% | -37.98% | -21.94% | -21.15% |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $996.65M | -22.90% | -17.96% | -22.57% | -25.02% |
| Vor Biopharma Inc. (VOR)vs › | $992.14M | 130.50% | -115.89% | -79.68% | -67.37% |
| Immatics N.V. (IMTX)vs › | $1.01B | -43.17% | -16.38% | -11.13% | -30.16% |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $982.46M | -23.69% | -98.11% | -69.18% | -69.18% |
| MeiraGTx Holdings plc (MGTX)vs › | $981.66M | 19.92% | -50.75% | -41.99% | -34.79% |
| Castle Biosciences, Inc. (CSTL)vs › | $1.02B | -3.46% | -0.37% | -7.11% | -6.26% |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $978.09M | N/A | N/A | N/A | N/A |
| Pacira BioSciences, Inc. (PCRX)vs › | $973.93M | 1.18% | -2.92% | -0.56% | 1.87% |
| Janux Therapeutics, Inc. (JANX)vs › | $1.02B | -10.18% | -8.89% | -12.61% | -16.81% |
ROA
-56.3%
ROE
-63.6%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -49.04% |
| 2024-12-31 | -26.92% |
| 2023-12-31 | -31.63% |
| 2022-12-31 | 19.82% |
| 2021-12-31 | -15.00% |
| 2020-12-31 | -24.13% |
| 2019-12-31 | -19.95% |
| 2018-12-31 | -40.96% |
